Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 14, 2011, Pages 5777-5782

  Hoffmann, Hans Heinrich ^a   Kunz, Andrea ^a,b   Simon, Viviana A ^a   Palese, Peter ^a   Shaw, Megan L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CELL PROTEIN; DIHYDROOROTATE DEHYDROGENASE; PYRIMIDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; BIOSYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DENGUE VIRUS; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SINDBIS VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS INHIBITION; VIRUS REPLICATION; WEST NILE FLAVIVIRUS;

DENGUE VIRUS; DNA VIRUSES; HEPATITIS C VIRUS; HUMAN ADENOVIRUS; MAMMALIA; NEWCASTLE DISEASE VIRUS; ORTHOMYXOVIRIDAE; RNA VIRUSES; SINDBIS VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; WEST NILE VIRUS;

EID: 79955032440     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1101143108     Document Type: Article

References (32)

1. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
2. Bright RA, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 366: 1175-1181. (Pubitemid 41393595)
3. Wolf MC, et al. (2010) A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA 107:3157-3162.
4. St Vincent MR, et al. (2010) Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 107:17339-17344.
5. Sidwell RW, et al. (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-Dribofuranosyl- 1,2,4-triazole-3-carboxamide. Science 177:705-706.
6. Reichard O, Schvarcz R, Weiland O (1997) Therapy of hepatitis C: Alpha interferon and ribavirin. Hepatology 26(3, Suppl 1):108S-111S. (Pubitemid 27388082)
7. Toltzis P, O'Connell K, Patterson JL (1988) Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob Agents Chemother 32:492-497. (Pubitemid 18089353)
8. Crotty S, et al. (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375-1379. (Pubitemid 32001022)
9. Streeter DG, et al. (1973) Mechanism of action of 1-β-D- ribofuranosyl-1,2,4-triazole-3- carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 70:1174-1178.
10. Leyssen P, Balzarini J, De Clercq E, Neyts J (2005) The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947. (Pubitemid 40459141)
11. Gowen BB, et al. (2007) In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 51:3168-3176. (Pubitemid 350067524)
12. Furuta Y, et al. (2009) T-705 (favipiravir) and related compounds: Novel broadspectrum inhibitors of RNA viral infections. Antiviral Res 82:95-102.
13. Furuta Y, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981. (Pubitemid 34260339)
14. Kiso M, et al. (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107:882-887.
15. Qing M, et al. (2010) Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother 54:3686-3695.
16. Knight DA, et al. (2001) Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 71:170-174. (Pubitemid 32105800)
17. Waldman WJ, et al. (1999) Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 42:412-418. (Pubitemid 30122078)
18. Waldman WJ, et al. (1999) Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 68:814-825. (Pubitemid 29468200)
19. Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES (2005) Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res 65:1-12. (Pubitemid 40094769)
20. McLean JE, Neidhardt EA, Grossman TH, Hedstrom L (2001) Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry 40:2194-2200. (Pubitemid 32165690)
21. Greene S, Watanabe K, Braatz-Trulson J, Lou L (1995) Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50:861-867.
22. Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J (2000) Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 8:25-33. (Pubitemid 30051339)
23. Knecht W, Löffler M (1998) Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem Pharmacol 56:1259-1264. (Pubitemid 28511250)
24. Evans DR, Guy HI (2004) Mammalian pyrimidine biosynthesis: Fresh insights into an ancient pathway. J Biol Chem 279:33035-33038. (Pubitemid 39062943)
25. Li J, et al. (2007) Identification and characterization of human uracil phosphoribosyltransferase (UPRTase). J Hum Genet 52:415-422. (Pubitemid 46669304)
26. Herrmann ML, Schleyerbach R, Kirschbaum BJ (2000) Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 47:273-289. (Pubitemid 30394543)
27. Hoffmann HH, Palese P, Shaw ML (2008) Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res 80:124-134.
28. König R, et al. (2010) Human host factors required for influenza virus replication. Nature 463:813-817.
29. Traut TW, Jones ME (1996) Uracil metabolism-UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: Enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol 53:1-78.
30. Mulder LC, Harari A, Simon V (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci USA 105:5501-5506. (Pubitemid 351753892)
31. Marukian S, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48:1843-1850.
32. Harari A, Ooms M, Mulder LC, Simon V (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 83:295-303.